According to the World Health Organization (WHO) between 30% to 50% of cancers could be preventable1.
Launched in September 2022, the “Cancer Prevention Across Europe” campaign (PrEvCan) aims to help address this statistic and reduce the burden of cancer. Initiated, and led, by the European Oncology Nurses Society (EONS) we were delighted to speak with the campaign Project Lead, Lena Sharp, RN, (Regional Cancer Center Stockholm Gotland, Stockholm, Sweden) to learn more about the initiative and to help support EONS in raising awareness of PrEvCan amongst healthcare professionals (HCPs).
- Could you give us a brief overview of PrEvCan and its aims? (0.23)
- What is the role of EONS and ESMO in this campaign? (1:11)
- Could you tell us a little about the European Code of Cancer (ECAC) on which PrEvCan is based? (1:47)
- What will be the focus for the coming months? (2:36)
We continue our conversation here, addressing the importance of nurses, partnerships and funding in the campaign’s success.
Disclosures: Lena Sharp has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival
Share this Video
Related Videos In Policy
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
The PrEvCan – Cancer Prevention Across Europe – campaign, initiated by the European Oncology Nursing Society (EONS) and supported by ESMO, aims to reduce the burden of cancer by promoting a different way we can decrease cancer risk each month. This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus […]
Vivek Subbiah, AACR 2023: The purpose of phase I clinical trials
The purpose of phase I clinical trials are to evaluate the safety, dosage and potential side effects of a new drug or treatment in humans for the first time. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) to discuss the purpose and details […]
Vivek Subbiah, AACR 2023: The evolution of phase I clinical trials in the era of precision medicine
Precision medicine aims to tailor medical treatments to individual patients based on their characteristics and genetic makeup. Phase I clinical trials are seeing changes in their objectives and designs in the era of precision medicine. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!